Shuttle Pharmaceuticals Net Worth
Shuttle Pharmaceuticals Net Worth Breakdown | SHPH |
Shuttle Pharmaceuticals Net Worth Analysis
Shuttle Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Shuttle Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Shuttle Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Shuttle Pharmaceuticals' net worth analysis. One common approach is to calculate Shuttle Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Shuttle Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Shuttle Pharmaceuticals' net worth. This approach calculates the present value of Shuttle Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Shuttle Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Shuttle Pharmaceuticals' net worth. This involves comparing Shuttle Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Shuttle Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Shuttle Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Shuttle Pharmaceuticals' net worth research are outlined below:
| Shuttle Pharmaceuticals generated a negative expected return over the last 90 days | |
| Shuttle Pharmaceuticals has high historical volatility and very poor performance | |
| Shuttle Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Shuttle Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Shuttle Pharmaceuticals currently holds 1.09 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Shuttle Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Shuttle Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (6.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Shuttle Pharmaceuticals currently holds about 50.44 K in cash with (5.58 M) of positive cash flow from operations. | |
| Shuttle Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of Shuttle Pharmaceuticals outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Why Five9 Shares Are Trading Higher By Around 13 Here Are 20 Stocks Moving Premarket - Benzinga India |
Shuttle Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Shuttle Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Shuttle Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Shuttle Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Shuttle Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Shuttle Pharmaceuticals backward and forwards among themselves. Shuttle Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Shuttle Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 306.1 K | Ubs Group Ag | 2024-12-31 | 32.8 K | Geode Capital Management, Llc | 2024-12-31 | 10.9 K | Tower Research Capital Llc | 2024-12-31 | 6.9 K | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-12-31 | 23.0 | Hrt Financial Llc | 2024-12-31 | 0.0 |
Follow Shuttle Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.46 M.Market Cap |
|
Project Shuttle Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.00) | (1.05) | |
| Return On Capital Employed | (1.08) | (1.13) | |
| Return On Assets | (1.00) | (1.05) | |
| Return On Equity | (1.46) | (1.54) |
When accessing Shuttle Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Shuttle Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Shuttle Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Shuttle Pharmaceuticals' management efficiency
Shuttle Pharmaceuticals has return on total asset (ROA) of (1.1184) % which means that it has lost $1.1184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2785) %, meaning that it created substantial loss on money invested by shareholders. Shuttle Pharmaceuticals' management efficiency ratios could be used to measure how well Shuttle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.05. The current Return On Capital Employed is estimated to decrease to -1.13. As of now, Shuttle Pharmaceuticals' Net Tangible Assets are increasing as compared to previous years. The Shuttle Pharmaceuticals' current Total Current Assets is estimated to increase to about 6.8 M, while Other Assets are projected to decrease to 5,184.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.23 | 0.24 | |
| Tangible Book Value Per Share | 0.23 | 0.24 | |
| Enterprise Value Over EBITDA | (12.72) | (13.36) | |
| Price Book Value Ratio | 16.42 | 15.60 | |
| Enterprise Value Multiple | (12.72) | (13.36) | |
| Price Fair Value | 16.42 | 15.60 | |
| Enterprise Value | 64.9 M | 61.6 M |
Effective leadership at Shuttle Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Shuttle Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Shuttle Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Shuttle Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dritschilo Anatoly over three months ago Disposition of 8372 shares by Dritschilo Anatoly of Shuttle Pharmaceuticals at 1.605 subject to Rule 16b-3 | ||
Lorber Timothy J. over six months ago Disposition of tradable shares by Lorber Timothy J. of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Schafer Joshua over six months ago Disposition of tradable shares by Schafer Joshua of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Vander Hoek Michael over six months ago Acquisition by Vander Hoek Michael of 100000 shares of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Jacobs Bette over a year ago Sale by Jacobs Bette of 4157 shares of Shuttle Pharmaceuticals | ||
Dritschilo Anatoly over a year ago Bona fide gift to Dritschilo Anatoly of 2100000 shares of Shuttle Pharmaceuticals subject to Section 16 | ||
Brown Milton over a year ago Acquisition by Brown Milton of 25000 shares of Shuttle Pharmaceuticals subject to Rule 16b-3 |
Shuttle Pharmaceuticals Earnings per Share Projection vs Actual
Shuttle Pharmaceuticals Corporate Management
| Michael Starkweather | VP Devel | Profile | |
| CSC MD | Chief CoFounder | Profile | |
| Timothy CPA | Chief Officer | Profile | |
| Gene Esq | General Counsel | Profile | |
| Mira Jung | CoFounder Biology | Profile | |
| Tyvin MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.